Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Eltrombopag in Chinese Chronic ITP Patients
NCT01762761Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Eltrombopag with Placebo (2 arms). Primary endpoint: Number of Participants Achieving a Platelet Count >=50x10^9/L After the First 6 Weeks of Stage 1. Started Feb 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01762761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01762761.